2023 World Conference on Lung Cancer (Posters)-P2.09. Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China

P2.09. Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China - PDF(Slides)

Pdf Summary

This document summarizes a study presented at the World Conference on Lung Cancer comparing the clinical benefits of amivantamab, a bispecific antibody targeting EGFR and MET, with real-world therapies in China for patients with advanced non-small cell lung cancer (NSCLC) and EGFR Exon20ins mutations. These mutations are associated with poor prognosis and resistance to EGFR tyrosine kinase inhibitors. The study included patients from the CHRYSALIS trial who received amivantamab and an external cohort (EC) of patients who received systemic anti-cancer therapy (SACT).<br /><br />The results showed that patients treated with amivantamab had significantly improved progression-free survival, time to next therapy, and overall response rate compared to patients who received current real-world therapies in the post-platinum-based chemotherapy setting in China. These findings were consistent when comparing the CHRYSALIS Asian subset to the EC.<br /><br />The study population included adult patients who had previously received platinum-based chemotherapy and met the eligibility criteria of the CHRYSALIS trial or the EC. Statistical analysis was performed to adjust for confounding factors such as age, gender, smoking status, and number of prior lines of therapy.<br /><br />The authors acknowledge the support of the patients and staff involved in the study and disclose relevant financial interests. The study had some limitations, including small patient numbers and potential bias typical for real-world studies.<br /><br />In conclusion, this study demonstrates the clinical benefits of amivantamab in comparison to real-world therapies for patients with NSCLC and EGFR Exon20ins mutations in China. The results underscore the need for more effective treatment options in this specific population.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

bispecific antibody

EGFR

MET

non-small cell lung cancer

NSCLC

EGFR Exon20ins mutations

clinical benefits

real-world therapies

China